- Celldex press release ( NASDAQ: CLDX ): Q4 GAAP EPS of -$0.56 beats by $0.03 .
- Revenue of $1.61M (+387.9% Y/Y) beats by $1.35M .
- Cash, cash equivalents and marketable securities as of December 31, 2022 were $305.0 million compared to $323.5 million as of September 30, 2022.
- Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2022 are sufficient to meet estimated working capital requirements and fund planned operations through 2025, which include our ongoing Phase 1b studies in urticaria and prurigo nodularis and our ongoing and planned Phase 2 studies in CSU, CIndU and EoE.
- Shares +3.95% AH.
For further details see:
Celldex GAAP EPS of -$0.56 beats by $0.03, revenue of $1.61M beats by $1.35M